Skip to content

Canada – EN logo

Main menu
    • About us
    • Our mission, vision & values
    • HER Professional Journey
    • Our leaders
    • Transparency
    • Environmental, Social & Governance
    • Diversity, equity, inclusion & belonging
  • Our products
  • Media
  • Join our team

Contact us

Visit Organon's LinkedIn Opens a new window

Back
Change Language
  • Français
Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:
News Release

March 3, 2023

Organon Canada receives the Women in Governance (WiG) Parity Certification SME, further demonstrating its commitment to gender parity in the workplace

The WiG evaluation, which comprises over 75 quantitative and qualitative criteria, showcases Organon Canada’s consideration for the multiple impacts of diversity and intersectionality on career advancement opportunities for women

Download Press Release

Kirkland, Quebec, March 2, 2023 – Organon Canada, a subsidiary of Organon (NYSE: OGN), a global women’s health company, is excited to share that in line with National Employee Appreciation Day on March 3, it has received the Women in Governance Parity Certification SME.1 The WiG Parity Certification SME is a national benchmark recognizing notable organizations for their ongoing efforts and commitments to gender parity in the workplace. Through integrating numerous programs and policies across the organization, Organon Canada has successfully achieved an industry-renowned standard of excellence for continued progress and work to date in moving the needle around enhancing and sustaining gender parity in the workplace.

“This recognition is a strong testament to our ongoing commitment to gender equity in the workplace and beyond”, says Michael Casia, President and Managing Director at Organon Canada. “At Organon Canada, our mission is to deliver impactful solutions which help to envision a better and healthier every day for everyone, with a focus on women. This includes supporting and amplifying the voices of women while maintaining a continued focus and emphasis on opportunities for their leadership and advancement at all levels of the organization. For me, attaining the WiG Parity Certification SME signifies that Organon Canada is on the right track – which is certainly something to celebrate this National Employee Appreciation Day. As we continue to strive for balanced gender representation across our entire organization by 2030, we will seek to further strengthen our longer-term roadmap, ensuring future efforts on this front fall closely in line with the UN’s Sustainable Development Goal around gender equality.”

WiG’s Parity Certification SME provides a holistic assessment of an organization’s endeavors by reviewing several primary drivers which directly assess its current position on gender parity, including its strategies around culture and commitments to enable more progressive and equitable representation. From there, WiG also reviews an organization’s actions to date around communications, policy and programs in place which work to facilitate progress and drive meaningful results related to diversity, equity and inclusion.

“Women are at the centre of and represent the heart and soul of our organization,” mentions Litsa Spiridonakos, Director of Human Resources at Organon Canada. “The journey to improve women’s health is fundamental to achieve gender equity in our communities and within our own walls. We’re proud that 66% of Organon Canada’s employees are women, 54% of our people managers are women, and our global Board of directors is composed of 69% women. We aim to maintain a gender balance coinciding with diverse and intersectional representation amongst our employee base, while actively working to increase the number of women in mid- and senior leadership roles throughout our organization by creating an environment where they can thrive.”

For Organon Canada, establishing itself as a partner of choice for women’s health and gender equity is a foundational goal that is critical to the success and endeavours of the organization. With International Women’s Day quickly approaching, and this year’s global campaign theme being Embrace Equity, Organon Canada is proud to be demonstrating its value of embracing gender equity as a top priority, not only on this celebratory day, but every day.

To learn more about Organon Canada’s vision and values as it relates to diversity, equity, inclusion and belonging.

About Organon

Organon is a global healthcare company with a focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, connect with us on LinkedIn.


Reference: 1. Women in Governance, The certification that is closing the gender parity in the workplace. Online, accessed February 2023.

Connect with us on social

Linkedin icon Opens a new window
Canada – EN logo

Company

  • About us
  • Our mission, vision & values
  • Her Professional Journey
  • Our leaders

Resources

  • Our products
  • Media

Contact information

  • Contact us
  • Join our team
  • Cookie Policy
  • Privacy Notice
  • Terms of Use
  • Terms and Conditions for Sales
  • Community Engagement Guidelines
  • Statement of Organon on Forced Labour
  • Sitemap
© 2025 Organon group of companies. All rights reserved.
CA-NON-110287

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept